Calidi Biotherapeutics, Inc. (CLDI) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Calidi Biotherapeutics, Inc. (CLDI) Earnings Overview
As of July 8, 2026, Calidi Biotherapeutics, Inc. (CLDI) reported trailing twelve-month net income of -$19M, reflecting +83.3% year-over-year growth. The company earned $-1.85 per diluted share over the past four quarters.
Looking at the long-term picture, CLDI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$8M in fiscal 2020.
Calidi Biotherapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), TGTX ($462M net income, 72.6% margin), ONCY (-$35M net income), CLDI has comparable earnings metrics. Compare CLDI vs IMVT →
CLDI Earnings vs Peers
Earnings metrics vs comparable public companies
CLDI Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$20M | +10.1% | -$20M | $-5.95 | - | - |
| 2024 | -$22M | +24.2% | -$22M | $-35.70 | - | - |
| 2023 | -$29M | -14.9% | -$29M | $-207.61 | - | - |
| 2022 | -$25M | -132.6% | -$23M | $-358.80 | -56504.4% | -51395.6% |
| 2021 | -$11M | -37.7% | -$10M | $14.16 | -2435.0% | -2334.5% |
| 2020 | -$8M | - | -$7M | $-2.64 | - | - |
Download Data
Export CLDI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CLDI — Frequently Asked Questions
Quick answers to the most common questions about buying CLDI stock.
What is CLDI earnings per share (EPS)?
CLDI trailing twelve-month (TTM) diluted EPS is $-1.85, reflecting +83.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Calidi Biotherapeutics, Inc.'s net income?
Calidi Biotherapeutics, Inc. (CLDI) trailing twelve-month net income is $-19M as of 2025. Earnings grew +83.3% year-over-year.
Is CLDI profitable?
CLDI is not currently profitable on a TTM basis, reporting a net loss of $-19M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CLDI's earnings growth rate?
CLDI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are CLDI's profit margins?
Calidi Biotherapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -695.2%.
Is CLDI growing earnings?
Yes, CLDI earnings are accelerating — EPS growth of +83.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-19M. Earnings momentum is strengthening.
What was CLDI's best earnings year?
Calidi Biotherapeutics, Inc.'s highest annual net income on record is $-8M, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were CLDI's earnings last quarter?
CLDI's most recent reported quarter was Q1 2026. Net income was $-4M with diluted EPS of $-0.43. For a full breakdown of all quarters, see the quarterly earnings table on this page.